Association between Serum Cortisol and DHEA-S Levels and Response to Antipsychotic Treatment in Schizophrenia
Keywords:schizophrenia, cortisol, DHEA-S, responders, nonresponders
BACKGROUND: Previous studies suggested that alterations in serum cortisol and DHEA-S levels may play a role in the pathophysiology of schizophrenia.
AIM: To compare serum cortisol and DHEA-S levels between patients with schizophrenia and healthy controls and to evaluate their association with the response to antipsychotic treatment.
MATERIAL AND METHODS: In this clinical prospective study were included 60 patients with schizophrenia and 40 healthy age and sex matched control subjects. Clinical evaluation of patients was performed using the Positive and Negative Symptom Scale. A questionnaire for socio-demographic and clinical data collection was used. For the purposes of the study, the examined group was divided in two subgroups: responders and nonresponders. Serum cortisol and DHEA-S levels were measured at baseline in all participants and after 3 and 6 weeks of the antipsychotic treatment in patients with schizophrenia.
RESULTS: Patients with schizophrenia had significantly higher serum cortisol and DHEA-S levels in comparison to the control group. Responders had significantly higher serum cortisol and DHEA-S levels compared with nonresponders.
CONCLUSION: Elevated serum cortisol and DHEA-S levels may play a role in the pathophysiology of schizophrenia and they may be related to positive response to antipsychotic treatment in patients with schizophrenia.
Plum Analytics Artifact Widget Block
Kaneko M, Yokoyama F, Hoshino Y et al. Hypothalamicpituitary-adrenal axis function in chronic schizophrenia: association with clinical features. Neuropsychobiology. 1992; 25: 1â€“7.
YÄ±ldÄ±rÄ±m O, Dogan O, Semiz M, Kilicli F. Serum cortisol and dehydroepiandrosterone-sulfate levels in schizophrenic patients and their first-degree relatives. Psychiatry Clin Neurosci. 2011; 65: 584â€“91.
Ryan MC, Sharifi N, Condren R, Thakore JH. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 2004; 29: 1065-70.
Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol Psychiatry. 2000; 48: 1121â€“32.
Gallagher P, Watson S, Smith MS, Young AH, Ferrier IN. Plasma cortisol-dehydroepiandrosterone (DHEA) ratios in schizophrenia and bipolar disorder. Schizophr Res. 2007; 90(1-3): 258-65.
Zhang XY, Zhou DF, Cao LY, Wu GY, Shen YC. Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology. 2005; 30(8): 1532-8.
Yilmaz N, Herken H, Cicek HK et al. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract. 2007; 16(2): 137-41.
Hori H, Teraishi T, Sasayama D et al. Elevated cortisol level and cortisol/DHEAS ratio in schizophrenia as revealed by low-dose dexamethasone suppression test. The Open Neuropsychopharmacology. 2012; 5: 18-24.
Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty T, Gangadhar BN. Effect of antipsychotic treatment on Insulin-like Growth Factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res. 2010; 119(1-3): 131-7.
Steen NE, Methlie P, Lorentzen S et al. Increased systemic cortisol metabolism in patients with schizophrenia and bipolar disorder: a mechanism for increased stress vulnerability? J Clin Psychiatry. 2011; 72(11): 1515-21.
Ritsner M, Maayan R, Gibel A et al. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients. Eur Neuropsychopharmacol. 2004; 14: 267â€“73.
Taherianfard M, Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients. Indian J Med Sci. 2004; 58(1): 3-9.
Morfin R. DHEA and the brain. Taylor and Francis: London and New York, 2002.
Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol. 1996; 150: S221â€“S239.
Rupprecht R. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology. 2003; 28: 139â€“68.
Ritsner M. Pregnenolone, Dehydroepiandrosterone, and Schizophrenia: Alterations and Clinical Trials. CNS Neurosci Ther. 2010; 16:32â€“44.
Oades RD, Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology. 1994; 19(4): 373-85.
Strous RD, Maayan R, Lapidus R et al. Increased circulatory dehydroepiandrosterone and dehydroepiandrosteronesulphate in first episode schizophrenia: relationship to gender, aggression and symptomatology. Schizophr Res. 2004; 71: 427â€“ 34.
Shirayama Y, Hashimoto K, Suzuki Y, Higuchi T. Correlation of plasma neurosteroids to the severity of negative symptoms in male patients with schizophrenia. Schizophrenia Res. 2002; 58: 69â€“74.
Ritsner M, Gibel A, Ram E et al. Alterations in DHEA metabolism in schizophrenia: Two-month case-control study. Eur Neuropsychopharmacol. 2006; 16: 137-46.
Ritsner M, Gibel A, Maayan R et al. Cortisol/Dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia. Neuropsychopharmacology. 2005; 30: 1913â€“22.
BeyazyÃ¼z M, Albayrak Y, BeyazyÃ¼z E, Ãœnsal C, GÃ¶ka E. Increased serum dehydroepiandrosterone sulfate in the first episode but not in subsequent episodes in male patients with schizophrenia. Neuropsychiatr Dis Treat. 2014; 10:687â€“93.
di Michele F, Caltagirone C, Bonaviri G, Romeo E, Spalletta G. Plasma dehydroepiandrosterone levels are strongly increased in schizophrenia. J Psychiatr Res. 2005; 39: 267-73.
Garner B, Phassuliotis C, Phillips LJ et al. Cortisol and dehydroepiandrosterone-sulphate levels correlate with symptom severity in first-episode psychosis. J Psychiatr Res. 2011; 45(2): 249-55.
Marx CE, Stevens RD, Shampine LJ et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006; 31: 1249-63.
Shulman Y, Tibbo P. Neuroactive steroids in schizophrenia. Can J Psychiatry. 2005; 50:695-702.
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13: 261â€“7.
Kaneda Y, Fujii A, Ohmori T. The hypothalamic-pituitaryadrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog. Neuropsychopharmacol Biol Psychiatry. 2002; 26: 935â€“8.
How to Cite
All rights reserved.